Access cutting-edge epithelial ovarian cancer treatment through this clinical trial at a research site in Pittsburgh. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Pittsburgh location
Preparing your pre-screening questions…
Access epithelial ovarian cancer specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related epithelial ovarian cancer treatment provided free
Check if you qualify for this epithelial ovarian cancer clinical trial in Pittsburgh, PA
No-Cost Study Care
Local to Pittsburgh
Convenient for PA residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
This study is researching an experimental CAR T cell therapy called 27T51, referred to as study drug. The study drug is a MUC16 targeting immune cell therapy focused on adult female participants with recurrent or difficult to treat epithelial ovarian, primary peritoneal or fallopian tube cancer. This study has two (2) major parts: Phase 1a Dose Escalation and Phase 1b Dose Expansion. The aim of the dose escalation part will be to test the safety of 27T51 in a small number of participants to find the highest dose given to humans without unacceptable side effects. The aim of the dose expansion part will be to test 27T51 at the established dose level(s) from the dose escalation part and may include other medications given in combination with 27T51. Information collected from this study will help researchers understand more fully whether this immune cell therapy, also known as CAR T cell therapy, can be safely used to treat solid tumors such as ovarian cancer.
Sponsor: Regeneron Pharmaceuticals
Yes, this clinical trial (NCT06469281) has an active research site in Pittsburgh, PA that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for epithelial ovarian cancer treatment options in Pittsburgh, PA, this clinical trial (NCT06469281) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Pittsburgh research site is actively enrolling participants for this clinical trial. You'll receive care from experienced epithelial ovarian cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all epithelial ovarian cancer clinical trials near you to find additional studies recruiting in your area.
See all ovarian cancer clinical trials recruiting in Pittsburgh — not just this study.
Browse Ovarian Cancer Trials in Pittsburgh →